Drug Trial Radar · NCT03329911
A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
651
Actual
Start
Oct 20, 2017
Primary completion
Nov 5, 2019
Study completion May 27, 2021
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706 to EU Avastin® in patients with previously untreated advanced non-squamous non-small cell lung cancer (nsNSCLC) to demonstrate clinical equivalence of BAT1706 and EU Avastin®.
Conditions
- Non-squamous Non-small Cell Lung Cancer
Interventions
EU Avastin®Drug
100 mg/4 mL
BAT1706Drug
100 mg/4 mL
PaclitaxelDrug
200 mg/m²
carboplatinDrug
target area under the curve \[AUC\] 6 mg/mL•minute
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: Week 18
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
The First Affiliated Hospital of Xiamen University
Xiamen, China
Clinical Medical Research S.C.
Orizaba, Mexico
National Hospital Oncology
Bloemfontein, South Africa
Baskent University Ankara Hospital
Ankara, Turkey (Türkiye)
CI Kryvyi Rih Oncological Dispensary of DRC
Kryvyi Rih, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.